CN Patent

CN102803247A — 组胺h3受体拮抗剂的新颖富马酸盐

Assigned to Sanofi Aventis France · Expires 2012-11-28 · 13y expired

What this patent protects

本发明涉及2-(环己基甲基)-N-{2-[(2S)-1-甲基吡咯烷-2-基]乙基}-1，2，3，4-四氢异喹啉-7-磺酰胺的富马酸盐、其药物组合物、其制备方法及其使用方法。

USPTO Abstract

本发明涉及2-(环己基甲基)-N-{2-[(2S)-1-甲基吡咯烷-2-基]乙基}-1，2，3，4-四氢异喹啉-7-磺酰胺的富马酸盐、其药物组合物、其制备方法及其使用方法。

Drugs covered by this patent

tapinarof (TAPINAROF)

Patent Metadata

Patent number: CN102803247A
Jurisdiction: CN
Classification: —
Expires: 2012-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.